Phillip Habib, MD
Advanced Heart Failure and Transplant Cardiology · Delray Beach, FLNPI 1326262874
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $269,026 of the $305,371 with a category attached, or 88.1%. 27 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 29.2% of the total. Among advanced heart failure and transplant cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 439 payments — averaging $695.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$89K
- AstraZeneca$63K
- Boehringer Ingelheim$40K
- Novartis$39K
- Actelion Pharmaceuticals US, Inc.$35K
- Pfizer$26K
- plus $14K from 21 others
Across 6 payments — averaging $5780.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$26K
- Alnylam Pharmaceuticals Inc.$8K
What the payments were for
- Consulting fees$9,9363%
- Speaking & faculty fees$269,02688%
- Travel & lodging$9,7083%
- Food & beverage$16,6075%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 69 | $89,207 |
| AstraZeneca | 57 | $62,558 |
| Boehringer Ingelheim | 32 | $39,537 |
| Novartis | 48 | $38,725 |
| Actelion Pharmaceuticals US, Inc. | 86 | $35,059 |
| Pfizer | 23 | $25,976 |
| Lilly USA, LLC | 11 | $9,062 |
| Abbott | 15 | $1,351 |
| Abiomed | 12 | $1,091 |
| Medtronic(2 entities) | 9 | $613 |
| United Therapeutics Corporation | 24 | $486 |
| Alnylam Pharmaceuticals Inc. | 25 | $441 |
| Cardiac Dimensions, Inc. | 1 | $159 |
| Elutia, Inc. | 1 | $149 |
| Heartflow, Inc. | 1 | $146 |
| ZOLL Respicardia, Inc. | 1 | $133 |
| Atricure, Inc. | 1 | $131 |
| Boston Scientific | 1 | $107 |
| Akcea Therapeutics, Inc. | 4 | $107 |
| Johnson & Johnson | 4 | $82 |
| Sandoz | 4 | $76 |
| Gilead | 3 | $63 |
| Bayer | 2 | $41 |
| Arbor Pharmaceuticals, Inc. | 2 | $28 |
| Edwards Lifesciences | 1 | $15 |
| Merck | 1 | $15 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$86,546
- FARXIGA$52,741
- JARDIANCE$48,251
- ENTRESTO$35,468
- VYNDAQEL$25,774
- OPSUMIT$14,729
- UPTRAVI$12,988
- WAINUA$9,552
- Impella$819
- HeartMate 3 Left Ventricular Dev$786
- MitraClip$188
- HeartWare HVAD$171
- ECM Patch,Pouch$149
- FFRct$146
- LINQ II$134
- AVEIR$133
- remede System$133
- ATRICLIP LAA EXCLUSION SYSTEM$131
- ORENITRAM$125
- GENERAL - THERAPIES$107
How this compares
$305,371 in reported general payments places this provider in the 95th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
See all advanced heart failure and transplant cardiology providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 76 | $2,271,208 |
| CamzyosMavacamten | 80 | $661,722 |
| OpsumitMacitentan | 50 | $618,550 |
| UptraviSelexipag | 28 | $583,070 |
| EliquisApixaban | 173 | $194,771 |
| AdempasRiociguat | 12 | $169,590 |
| EntrestoSacubitril/Valsartan | 105 | $143,792 |
| JardianceEmpagliflozin | 77 | $91,256 |
| FarxigaDapagliflozin Propanediol | 61 | $78,689 |
| Tadalafil | 17 | $25,077 |
| XareltoRivaroxaban | 16 | $25,011 |
| Repatha SureclickEvolocumab | 26 | $22,845 |
| BrilintaTicagrelor | 13 | $15,185 |
| Metoprolol Succinate | 207 | $2,609 |
| Rosuvastatin Calcium | 73 | $2,035 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $25,976 | $2,465,980249 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $35,059 | $1,201,62078 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $89,207 | $661,72280 claims |
| BayerAdempas | $41 | $169,59012 claims |
| NovartisEntresto | $38,725 | $143,792105 claims |
| AstraZenecaFarxiga, Brilinta | $62,558 | $93,87474 claims |
| Boehringer IngelheimJardiance | $39,537 | $91,25677 claims |
| Johnson & JohnsonXarelto | $82 | $25,01116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 advanced heart failure and transplant cardiology providers in Florida.
Other advanced heart failure and transplant cardiology in Delray Beach
- Kelly McCantsWinter Park$445K
- Naveen BellamOrlando$414K
- Waqas GhummanAtlantis$276K
- David SnipeliskyWeston$250K
- Elsy NavasNaples$234K
- David BaranWeston$116K
- Rohan GoswamiJacksonville$112K
- Tara Hrobowski-BlackmanLargo$102K
- Stacy MandrasOrlando$100K
- Omar Wever-PinzonMiami$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.